Targeting Mitochondrial Dysfunction

Our lead product, Imeglimin, is in Phase 3 development in Japan and has successfully completed Phase 2 development in the U.S. and EU.

View Candidate
Targeting Mitochondrial Dysfunction

Innovative Pipeline of First-In-Class Products

Our candidates are based on disease-modifying mechanisms of action that offer the potential for safer and more effective therapies for type 2 diabetes and NASH.

View Pipeline
Innovative Pipeline of First-In-Class Products

Backed by Strong Leadership

Our highly-experienced clinical and regulatory teams possess the know-how and experience to successfully develop products within our pipeline.

Meet Our Team
Backed by Strong Leadership

Latest News

Poxel Announces Updates to its Management Team

LYON, France--(BUSINESS WIRE)-- POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and…

Read this Press Release: Poxel Announces Updates to its Management Team

Poxel Announces Positive Topline Results for Imeglimin Phase 3 Trial (TIMES 3 36-week) for the Treatment of Type 2 Diabetes in Japan

Imeglimin in combination with insulin was observed to demonstrate consistent and sustained efficacy in the TIMES 3 36-week, open-label extension period These results build upon the positive results from the 16-week…

Read this Press Release: Poxel Announces Positive Topline Results for Imeglimin Phase 3 Trial (TIMES 3 36-week) for the Treatment of Type 2 Diabetes in Japan

Poxel Announces Presentation of PXL065 Phase 1a Results at the Liver Meeting® 2019

PXL065 observed to have a favorable safety, tolerability and pharmacokinetic (PK) profile in the Phase 1a trial PXL065 intends to utilize the 505(b)(2) regulatory pathway, which offers the opportunity for a…

Read this Press Release: Poxel Announces Presentation of PXL065 Phase 1a Results at the Liver Meeting® 2019
Click here to show the previous slide Click here to show the next slide